Core Viewpoint - Crinetics Pharmaceuticals, Inc. has announced a public offering of 7,620,000 shares at a price of $45.95 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering consists entirely of shares sold by Crinetics, with a 30-day option for underwriters to purchase an additional 1,143,000 shares [1]. - The expected closing date for the offering is around January 8, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for commercial activities related to the launch of PALSONIFY™, R&D of product candidates, and general corporate purposes, including capital expenditures and working capital [2]. - Crinetics may also consider using a portion of the proceeds for in-licensing, acquiring, or investing in complementary businesses or technologies, although there are no current commitments to do so [2]. Group 3: Company Overview - Crinetics Pharmaceuticals focuses on developing novel therapeutics for endocrine diseases and related tumors, with expertise in targeting G-protein coupled receptors (GPCRs) [6]. - The company's lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the FDA for adults with acromegaly who have not responded adequately to surgery [7]. - Crinetics has a pipeline of over 10 disclosed programs, including candidates for congenital adrenal hyperplasia and neuroendocrine tumors, addressing various endocrine conditions [7].

Core Insights - Crinetics Pharmaceuticals, Inc. is preparing to host a conference call on January 5, 2026, to discuss the commercialization of PALSONIFY, the first FDA-approved oral treatment for acromegaly, and to share results from the Phase 2 trial of atumelnant for congenital adrenal hyperplasia [1][6] Group 1: Company Overview - Crinetics focuses on developing treatments for endocrine diseases, utilizing small molecules that target G-protein coupled receptors (GPCRs) [2] - The company's pipeline includes atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, as well as CRN09682 for SST2 expressing tumors [2] Group 2: Financial Performance - Evercore ISI has maintained an "Outperform" rating for CRNX, raising the price target from $80 to $90, despite the stock price being $52.57 and a negative price-to-earnings (P/E) ratio of -10.29 [3] - The company has a high price-to-sales ratio of 2,856.31 and an elevated enterprise value to sales ratio of 2,816.08, indicating that investors are paying a premium for its sales [4] - Crinetics has a negative earnings yield of -9.72%, but maintains a low debt-to-equity ratio of 0.046, reflecting minimal reliance on debt [5] - The company exhibits a strong liquidity position with a current ratio of 15.12, indicating it can comfortably cover its short-term liabilities [5]

Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Successfully Reduce Glucocorticoid Dose to Physiologic Replacement Levels Atumelnant's Favorable Benefit/Risk Profile Was Maintained in Cohort 4 and Open-Label Exte ...

Group 1 - Crinetics Pharmaceuticals will host a conference call and webcast on January 5, 2026, to provide updates on PALSONIFY™ commercialization and disclose topline results from the Phase 2 trial of atumelnant [1][2] - PALSONIFY™ (paltusotine) is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [4] - Crinetics has a deep pipeline of over 10 disclosed programs, including atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682 for treating SST2 expressing neuroendocrine tumors [4] Group 2 - Crinetics Pharmaceuticals focuses on transforming the treatment of endocrine diseases and related tumors through patient-centered science [3] - The company specializes in discovering, developing, and commercializing novel therapies targeting G-protein coupled receptors (GPCRs) with tailored pharmacology [3]

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 13, 2026 at 9:45 a.m. Pacific Time. To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Cr ...

Core Insights - Crinetics Pharmaceuticals has initiated the CALM-CAH Phase 3 trial for atumelnant, a novel oral ACTH receptor antagonist aimed at treating classic congenital adrenal hyperplasia (CAH) [1][2] - The trial will assess atumelnant's effectiveness in normalizing adrenal androgen levels and reducing glucocorticoid levels to physiological ranges, setting a new standard for disease control assessment [2][3] - Atumelnant is the first small molecule ACTH receptor antagonist in late-stage clinical development, showing promising results in a Phase 2 study with significant reductions in key biomarkers [2][4] Company Overview - Crinetics Pharmaceuticals focuses on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs and innovative therapies [5] - The company has a robust pipeline, including its lead product PALSONIFY™ for acromegaly and atumelnant for CAH and ACTH-dependent Cushing's syndrome [6][7] - Crinetics has received Orphan Drug Designation from the FDA for atumelnant, highlighting its potential impact on rare diseases [3]

Core Insights - Crinetics Pharmaceuticals granted stock options and restricted stock units (RSUs) to new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan, totaling 39,575 shares in stock options and 26,525 RSUs [1][2] Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs and targeting G-protein coupled receptors (GPCRs) with small molecules [3] Product Pipeline - The lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for adults with acromegaly who have not responded adequately to surgery [4] - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors, with a pipeline that includes over 10 disclosed programs targeting various endocrine conditions [4]

Core Insights - Crinetics Pharmaceuticals has initiated a Phase 1/2 clinical trial for CRN09682, targeting SST2-positive neuroendocrine tumors and other solid tumors, marking a significant milestone for the company's nonpeptide drug conjugate platform [1][2] Company Overview - Crinetics Pharmaceuticals is focused on transforming the treatment of endocrine diseases and related tumors, leveraging expertise in G-protein coupled receptors (GPCRs) and small molecule design [5] - The company has a deep pipeline of over 10 disclosed programs, including PALSONIFY™ (paltusotine), which is the first oral treatment approved by the U.S. FDA for acromegaly [6][7] Drug Development - CRN09682 is a first-in-class, non-radioactive, nonpeptide drug conjugate designed to selectively bind to SST2-expressing tumor cells, releasing a potent cytotoxic agent, monomethyl auristatin E (MMAE), directly within the tumor [4] - The Phase 1/2 BRAVESST2 trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682, with up to 150 participants expected to be enrolled [3] Clinical Trial Details - The trial consists of a dose-escalation study to determine the maximum tolerated dose and a dose expansion phase to further evaluate CRN09682 in selected SST2-expressing tumor types [3] - Eligible patients must have metastatic or locally advanced disease progression following standard therapies, confirmed by somatostatin receptor imaging [3]

Core Insights - Crinetics Pharmaceuticals granted stock options and restricted stock units (RSUs) to new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan, totaling 37,675 shares in stock options and 25,300 RSUs [1][2] Group 1: Stock Options and RSUs - The stock options have an exercise price of $41.45 per share, equal to the closing price on November 10, 2025 [2] - Stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder in 36 equal monthly installments, contingent on continued employment [2] - RSUs will also vest over four years in equal annual installments starting on the one-year anniversary, subject to continued employment [2] Group 2: Company Overview - Crinetics Pharmaceuticals is focused on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs [3] - The company specializes in discovering and developing therapies targeting G-protein coupled receptors (GPCRs) with tailored pharmacology [3] - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for adults with acromegaly who have inadequate surgical responses [4] Group 3: Pipeline and Development - The company has a deep pipeline with over 10 disclosed programs, including atumelnant, which is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [4] - Additional discovery programs target various endocrine conditions, including neuroendocrine tumors, Graves' disease, polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications [4]

Core Insights - Crinetics Pharmaceuticals, Inc. will report its third quarter 2025 financial results on November 6, 2025, after market close, followed by a conference call at 4:30 p.m. ET to discuss the results and provide a business update [1] Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs [4] - The company specializes in discovering, developing, and commercializing novel therapies, particularly targeting G-protein coupled receptors (GPCRs) with small molecules [4] Product Pipeline - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [5] - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors [5] - The company has a deep pipeline of over 10 disclosed programs, including the late-stage investigational candidate atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [5] - Additional discovery programs target various endocrine conditions such as neuroendocrine tumors, Graves' disease, polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications [5]